摘要
目的探讨N-端脑钠肽前体(NT-pro BNP)和超声心动图参数监测蒽环类药物早期心脏毒性的临床意义。方法收集接受并完成4周期蒽环类药物化疗的恶性肿瘤患者36例,在化疗前,第1、2、4个疗程结束次日采血测定NT-pro BNP水平及监测超声心动图参数[左室射血分数(LEVF)、二尖瓣舒张早期流速峰值/二尖瓣舒张晚期流速峰值(E/A值)、E峰的减速时间(DT)和左室等容舒张时间(IRT)]变化。结果第1周期化疗后,患者的NT-pro BNP水平为(192.20±26.63)pg/ml,较化疗前明显升高(P<0.05);第4周期化疗后,NT-pro BNP水平为(312.90±53.65)pg/ml,较第1周期化疗后进一步升高(P<0.05)。与化疗前比较,患者第1、4周期化疗后的LVEF、E/A值、DT、IRT无明显变化,差异均无统计学意义(P>0.05)。结论 NT-pro BNP水平可以作为监测蒽环类药物早期心脏毒性的一个指标,而超声心动图参数在早期无明显变化。
Objective To explore the clinical significance of NT-proBNP and ultrasonic cardiogram monitoring early cardiotoxicity of anthracyclines. Methods 36 patients with malignant tumor who received and completed 4-cycle chemotherapy with anthracyclines were collected.NT-proBNP level were detected by taking blood and the change of parameter of ultrasonic cardiogram [left ventricular ejection fraction （LEVF）,E/A value,deceleration time of E peak （DT） and Left ventricular isovolumic relaxation time （IRT）] were monitored before chemotherapy and at the end of the first, second and fourth course of treatment to the next day. Results Compared with before chemotherapy, the NT-proBNP level after the first cycle of chemotherapy [（192.20±26.63） pg/ml] was significantly higher than that before chemothera-py [（76.50±19.22） pg/ml] （P〈0.05）;after the fourth cycle of chemotherapy,the NT-proBNP level [（312.90±53.65） pg/ml] was further higher than that after the first cycle of chemotherapy （P〈0.05）.LVEF,E/A,DT and IRTafter the first and fourth cycle of chemotherapy did not show significant change in patients,and the difference was not statistically signifi-cant （P〉0.05）. Conclusion NT-proBNP level can be used as an index for monitoring early cardiotoxicity of anthracy-clines,and the parameter of ultrasonic cardiogram does not show significant change at the early stage.
出处
《中国当代医药》
2015年第10期136-137,140,共3页
China Modern Medicine
基金
广东省深圳市科技创新委员会基金资助项目(JCYJ20140416094256901)
